Literature DB >> 6416696

Combination of dacarbazine, mitomycin C, 5-fluorouracil and vincristine in advanced colorectal cancer.

G Falkson, H L Pretorius, H C Falkson, H S Schoeman.   

Abstract

Thirty patients with advanced measurable colorectal cancer received monthly courses of a combination of dacarbazine, mitomycin C, 5-fluorouracil, and vincristine (FIVMit-Or). Four of the patients had received prior chemotherapy. Two patients were not evaluable for response. Objective response was obtained in four patients. Severe toxicity was encountered in 11 patients. It is concluded that unlike the four-drug combination of 5-fluorouracil, DTIC, vincristine and BCNU (FIVB), the present regimen did not have significant antitumour activity in advanced colorectal cancer.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6416696     DOI： 10.1007/BF00254206

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  4 in total

1.  Efficacy of dacarbazine imidazole carboxamide and mitomycin C combination therapy in patients with adenocarcinoma of the colon refractory to 5-fluorouracil therapy.

Authors:  J F Conroy; P I Roda; I Brodsky; S B Kahn; S I Bulova; E Pequignot
Journal:  Recent Results Cancer Res       Date:  1981

2.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

3.  Combination of dacarbazine and mitomycin in advanced colorectal cancer.

Authors:  H Bleiberg; M Clavel; C Nicaise; J Devriendt; J Michel; B Vanderlinden; M Rozencweig
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

4.  Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea (FIVB) in colon cancer.

Authors:  G Falkson; H C Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.